Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 February 2022 | Story Andrè Damons
Dr Jeanette Mmabosa Sebaeng
After graduating with her post-basic diploma in Forensic Nursing from the University of the Free State (UFS) in 2006, Dr Jeanette Mmabosa Sebaeng returned to the institution as its newly appointed Head of the School of Nursing.

Dr Jeanette Mmabosa Sebaeng, newly appointed Head of the School of Nursing at the University of the Free State (UFS), is a UFS alumna who believes that the skills and knowledge she has learned here and at other institutions where she has worked, would contribute towards the vision of the university. Dr Sebaeng assumed her new position in January 2022 and is  looking forward to working with Prof Gert van Zyl, Dean of the Faculty of Health Sciences, and the rest of the team in the school and the faculty.

Joining Kovsies

“I am so thrilled; some of the expected roles of this position include serving in some university management structures beyond the school and external stakeholders, and I look forward to the exposure and profound experiences I will receive in this institution,” says Dr Sebaeng. According to her, the decision to join Kovsies emanated from her envisaged personal and professional growth, mainly in the sphere of management and leadership in the nursing profession as well as in the university. “The organisational culture of ubuntu embedded in the UFS learning and teaching strategy resonates well with the saying in my culture: ‘Motho ke motho ka batho ba bangwe’ (I am because you are). The ubuntu principles of respect, caring, compassion, and dignity of others are in alignment with my personal values, and this in itself is an assurance that I will fit snuggly and thrive in the Kovsie environment.”

The University of the Free State’s vision of producing students who are professionally competent and globally employable, seems to be attainable. During my first two weeks in office, I received documents from Dubai, Philadelphia, and London for academic verification of our graduates who applied for job opportunities in these countries. This is fascinating, and I wish there could be a way of getting feedback from employers in these and other countries to determine if we are producing graduates with the desired attributes that are internationally comparable,” says Dr Sebaeng.

Looking forward

“The world of nursing education in the country is very small and there is a lot of interaction among members from different universities. I learned on one platform that the UFS School of Nursing has a state-of-the-art simulation laboratory rated number one and the best in the country and perhaps even in Southern Africa. I cannot wait to engage with both the staff and students about the use of the simulation laboratory; I would like to ensure its optimal use, while maintaining it for the benefit of the students.”

Visions and goals

As Head of the school, Dr Sebaeng hopes to provide leadership, guidance, and support to staff and students in the School of Nursing, and to ensure that the environment is warm and conducive to all. She is also looking forward to working harmoniously with the staff within the school, as she believes in an environment that enables all staff members to flourish in the expected academic activities.  “I will also ensure that I work according to the acceptable and recommended norms and standards of the nursing profession, which will be to the benefit of the School of Nursing and the nursing practice. For instance, good relations with the relevant stakeholders such as the FSDoH, clinical health facilities, and the South African Nursing Council, among others, remain crucial for the education and training of nursing students. All members’ views and inputs leading to the upscaling of the school will be valued,” states Dr Sebaeng.

Dr Sebaeng, who previously worked as a lecturer and researcher at the North-West University (NWU), says there is a vast difference between her current position and the previous one. According to her, her current position brings more responsibilities, including leading, guiding, and making decisions that should yield tangible, set goals aligned with the vision of the university.

A mother of two and grandmother of a handsome two-year-old grandson, Dr Sebaeng is adventurous and loves travelling outside the country, with an outgoing personality to match. Cooking and trying out new dishes with her family is also very satisfying. She also loves interacting with young children, which led her to teaching Sunday school for 30 years. “My life mainly revolves around church, home, and work,” says Dr Sebaeng.

The impact of COVID-19 on nurses

Nursing education teaches nurses to be competent, knowledgeable, and to acquire relevant skills that enable them to assume their professional role with confidence. However, nurses also require optimal health to provide quality care to our societies. “The outbreak of COVID-19 has taught us that nursing in South Africa lacks systems aimed at developing resilience and coping mechanisms during pandemics. Most nurses were and still are scared that they may contract the virus and infect their own families, or even worse, die themselves. Nursing education institutions must include workable psychological interventions in the teaching of student nurses, which will assist nurses to survive during future pandemics. Despite this, clinical practices must try to alleviate compassion fatigue, work-related stress, and burnout experienced by nurses, in order to render optimal health care and to continue to be functional in their daily activities.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept